The hepatic encephalopathy market is projected to grow steadily at a 1.2% CAGR through 2036, fueled by increasing cases of chronic liver diseases and cirrhosis globally. Advances in early diagnosis and the introduction of new therapies like VE303, YAQ007, and GR3027 are expected to transform treatment options and expand the market. The U.S. leads the market with 60% share and about 210,000 cases in 2025, with numbers expected to rise. Emerging drugs aim to address unmet needs, potentially improving patient outcomes and reshaping the market landscape.
Perplexity AI CEO Aravind Srinivas shared lessons from Nvidia's Jensen Huang and Tesla's Elon Musk, highlighting Huang's mindset of running Nvidia as if it could fail within 30 days despite its $5 trillion valuation and advanced technology. Srinivas ...
Meta Platforms introduced an AI-powered feature called "AI Mode" within Facebook Search, which uses Meta's AI model Muse Spark to provide answers from public content rather than traditional search results. This innovation could generate over $10 bill...
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
